RxDoctor Payments Data

Alicia Olson

Psychiatric/Mental Health · Grand Junction, CONPI 1871010066

Payments from drug & device makers

$1,569in general payments, 2019–2025

Across 54 payments — averaging $29.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$405
  • Neurocrine Biosciences, Inc.$308
  • AbbVie$240
  • Teva Pharmaceuticals USA, Inc.$231
  • Otsuka America Pharmaceutical, Inc.$104
  • Lundbeck LLC$72
  • plus $211 from 8 others

What the payments were for

  • Food & beverage$1,42191%
  • Education$1489%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,569 in reported general payments places this provider in the 80th percentile of 873 psychiatric/mental health providers in Colorado.

See all psychiatric/mental health providers in Colorado

Medicare billing

Part B allowed, 2024
$16,648
Medicare patients
43
Services billed
165

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole12$40,540
VraylarCariprazine Hcl28$34,317
CaplytaLumateperone Tosylate14$22,888
NuedextaDextromethorphan Hbr/Quinidine12$19,173
BelsomraSuvorexant28$11,923
AuvelityDextromethorphan Hbr/Bupropion11$11,557
FetzimaLevomilnacipran Hcl11$5,424
Lurasidone Hcl16$4,573
Aripiprazole76$3,562
Lisdexamfetamine Dimesylate12$3,119
Duloxetine Hcl93$2,296
Bupropion XlBupropion Hcl70$2,145
Pilocarpine Hcl14$1,134
Lamotrigine120$1,078
Trazodone Hcl113$1,031

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$104$40,54012 claims
AbbVieVraylar, Fetzima$240$39,74139 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$405$22,88814 claims
Axsome Therapeutics, Inc.Auvelity$41$11,55711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 873 psychiatric/mental health providers in Colorado.

Other psychiatric/mental health in Grand Junction

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →